International Regulator Consortium Eyes Real-World Data
Lessons To Be Learned From Use Of COVID-19 Flexibilities
Executive Summary
The five-member ACCESS Consortium has outlined how it intends to build on its work-sharing experiences by applying innovative regulatory practices to the assessment of increasingly complex medicinal products.
You may also be interested in...
International Regulators Say Collaboration Is Key To Tackling Pharma Globalization Challenges
Regulators from Canada, the UK and Australia discuss their experiences of working together under both the ACCESS Consortium, an international regulatory worksharing coalition, and Project Orbis, a parallel review process designed to speed up access to oncology medicines.
International Regulators Explain Work-Sharing Scheme For Biosimilars
New guidance from the ACCESS Consortium of regulators from five countries explains how biosimilar drug sponsors can apply for an internationally-coordinated review of new products.
International Regulators Explain Work-Sharing Scheme For Biosimilars
New guidance from the ACCESS Consortium of regulators from five countries explains how biosimilar drug sponsors can apply for an internationally-coordinated review of new products.